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 MDR Acinetobacter baumannii infections represents a challenge for physicians  
 Bloodstream infections are related to high rates of septic shock and mortality  
 Data highlight a predominant role for colistin in definitive antibiotic regimens 
 Lack of scientific data might explain the very high mortality rate observed  
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Objectives: bloodstream infections (BSI) due to multidrug-resistant (MDR) Acinetobacter baumannii 
(AB) have been increasingly observed among hospitalized patients. 
Methods: prospective, observational study conducted among 12 large tertiary-care hospitals, across 7 
Italian regions. From June 2017 to June 2018 all consecutive hospitalized patients with bacteremia due to 
MDR-AB were included and analyzed in the study.  
Results: During the study period 281 episodes of BSI due to MDR-AB were observed: 98 (34.8%) 
episodes were classified as primary bacteremias, and 183 (65.2%) as secondary bacteremias; 177 (62.9%) 
of them were associated with septic shock. Overall, 14-day mortality was observed in 172 (61.2%) 
patients, while 30-day mortality in 207 (73.6%) patients. On multivariate analysis, previous surgery, 
continuous renal replacement therapy, inadequate source control of infection, and pneumonia were 
independently associated with higher risk of septic shock. Instead, septic shock and Charlson 
Comorbidity Index >3 were associated with 14-day mortality, while adequate source control of infection 
and combination therapy with survival. Finally, septic shock, previous surgery, and aminoglycoside-
containing regimen were associated with 30-day mortality, while colistin-containing regimen with 
survival. 
Conclusions: BSI caused by MDR-AB represents a difficult challenge for physicians, considering the 
high rates of septic shock and mortality associated with this infection.  
 



















In recent years, bloodstream infections (BSI) due to multidrug-resistant (MDR) gram-negative bacteria 
such as Acinetobacter baumannii (AB) have been increasingly observed among hospitalized patients 
admitted to the intensive care unit (ICU), surgical and medical wards [1-2-3]. MDR-AB has been defined 
one of the top priority pathogens by the World Health Organization [4-5]; specifically, in Italy an 
increased incidence of MDR-AB was observed in the last years [6].  
Acinetobacter baumannii bacteria are usually resistant to carbapenems and to β-lactams, 
aminoglycosides, rifampin, and fluoroquinolones [7-8]. There are limited therapeutic options resulting 
often in inappropriate therapy and subsequent negative impact on outcome. New agents with 
microbiological activity against MDR-AB strains have been recently developed and they will be available 
in the near future [9-10-11]. Mortality rate over 60% has been reported for MDR-AB infections [12], 
particularly in patients with septic shock [13]. 
Early diagnosis and adequate administration of antimicrobials are the milestone for the management of 
critically ill patients with MDR-AB [14-15-16], and recent data were reported in literature comparing 
monotherapy with combination therapy [17]. On these basis, physicians should recognize peculiar clinical 
characteristics and treat MDR-AB infections appropriately in hospitalized patients [18], so the aim of the 
present study was to analyse clinical features, antimicrobial treatment and outcome of patients with BSI 



















PATIENTS AND METHOD 
Study Design and Patient Selection 
Prospective, observational study conducted among 12 large tertiary-care hospitals across 7 Italian regions. 
From June 2017 to June 2018 all consecutive hospitalized patients with bacteremia caused by MDR-AB 
were included in the study. Inclusion criteria included: 1) age ≥18 years; 2) blood culture positive for 
MDR-AB; 3) clinical signs consistent with infection. Polymicrobial etiology was excluded; only one 
episode of MDR-AB infection for each patient was reported in the study period. The study was conducted 
according to the principles stated in the Declaration of Helsinki and has been approved by local Ethical 
Committees (No 4547-2017); informed consent was waived by Ethical Committees. The present study 
was promoted by ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana 
Terapia Antinfettiva). 
Patient data were collected from medical charts and from hospital computerized databases or clinical 
charts according to a pre-established questionnaire. The following information were reviewed: 
demographics; clinical and laboratory findings; comorbid conditions; microbiological data; duration of 
ICU and hospital stay; any  MDR infection during hospitalization; treatment and procedures (e.g. non-
invasive ventilation, mechanical ventilation, continuous renal replacement therapy [CRRT]) carried out 
during hospitalization and/or in the 30 days prior to infection; class of antibiotics received on admission 
and/or during admission before a positive culture of a biological sample was obtained; the simplified 
acute physiology score (SAPS II); sequential organ failure assessment (SOFA) and quick (q)-SOFA at 
time of infection; anamnestic MDR-AB colonization or during hospitalization; source of infection and its 
adequate control; antibiotic regimens used for MDR-AB infection; development of septic shock; all-cause 














Definitions and MDR-AB Identification 
Infections were defined according to the standard definitions of the European Centers for Disease Control 
and Prevention (eCDC) [19]. 
Infection was defined as the presence of at least 1 positive blood culture for MDR-AB in individuals with 
signs and symptoms consistent with infection [20]; concomitant isolation of MDR-AB in other sites like 
urine, skin swabs or biopsies, lung or abdomen were also recorded. Infection onset was defined as the 
date 
of collection of the first positive blood culture for MDR-AB. Infection was considered of unknown origin 
when the source of infection was not established after routine clinical, microbiological, and radiological 
examination. Primary BSI was defined as BSI occurring in patients without a recognized source of 
infection. The central venous catheter (CVC) was considered the source of infection if one of the 
following condition were present: 1) a positive result of semi-quantitative (> 15 colony-forming units per 
catheter segment) catheter culture, whereby the same species was isolated from the catheter segment and 
a peripheral blood culture; 2) growth in a blood culture obtained through a catheter hub is detected by an 
automated system at least 2 hours earlier than a peripheral blood culture of equal volume simultaneously 
collected, providing that the same species was isolated [21]. 
Septic shock was defined according to international definitions [22]. The severity of clinical conditions 
was determined by using SAPS II, SOFA and qSOFA scores calculated at the time of infection onset. 
Length of hospital and ICU stay were calculated as the number of days from the date of admission to the 
date of discharge or death.  
Identification of MDR-AB strains was based accordingly with local laboratory techniques. The Vitek 2 
automated system (bioMérieux, Marcy l’Etoile, France) was used for isolate identification and 













according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints 
[23]. Isolated strains were classified as multidrug-resistant (MDR), extensively drug-resistant (XDR) and 
pandrug-resistant (PDR) according to Magiorakos et al [24].  
 
 
Antimicrobial Treatment Evaluation and Adequate Source Control of Infection 
Depending on the number of drugs used (1 or >1), treatment regimens were classified either as 
monotherapy or combination therapy. Initial antibiotic therapy, defined as antimicrobial chemotherapy 
implemented within 24 hours after the onset of infection, was assessed along with definitive antibiotic 
therapy, defined as antimicrobial treatment based on in vitro MDR-AB isolate susceptibilities. Drugs in 
definitive therapy must have been administered for at least 50% of the total duration of therapy (except 
for patients who died while on definitive therapy, who were included if they received at least 1 complete 
day of therapy). Time to initial definitive therapy was the period between the infection onset and initial 
definitive therapy. 
Adequate control of source of infection was defined as the removal of any preexisting contaminated CVC 
as well as the drainage of intra-abdominal abscesses or other fluid collections have been performed within 
24 hours after the onset of infection. Timing of CVC removal was based on medical record review and 
was confirmed by review of patient radiographs. 
 
Primary Endpoint and Statistical Analysis  
The primary endpoint of the study was to evaluate risk factors associated with survival or death at 30 days 
from BSI onset. Secondary endpoints were risk factors associated with 14-day mortality and septic shock. 
To detect significant differences between groups, we used Chi-square test or Fisher exact test for 













appropriate. All pre-treatment variables identified at univariate analysis were tested at logistic regression 
analysis to identify risk factors associated with development of septic shock. In a multivariate analysis of 
survival, the Cox regression model was tested using a proportional hazards model analysis with backward 
stepwise selection and p <0.05 for all variables, to determine the effects of all anamnestic, clinical and 
therapeutic variables on 14- and 30-day survival. Kaplan-Meier curves were used to determine survival at 
14- and 30-day in patients treated either with monotherapy or combination therapy. Survival curves for 
time-to-event variables, constructed with the use of Kaplan–Meier estimates, were based on all available 
data and were compared with the use of the log-rank test. Wald confidence intervals and tests for hazard- 
and odds-ratios were computed based on the estimated standard errors. Possible confounding factors and 
interactions were weighted during analyses. Statistical significance was established at ≤ 0.05. All reported 
P values are 2-tailed. The results obtained were analyzed using a commercially available statistical 
































During the study period, 281 BSI caused by MDR-AB strains were observed. Out of these, 98 episodes 
(34.8%) were classified as primary bacteremia, and 183 (65.2%) cases as secondary bacteremia; 177 
(62.9%) episodes were associated with development of septic shock. Resistance rates were the following: 
colistin 1.4%, gentamicin 87.3%, amikacin 89.1%, and meropenem 100%. On these basis, 98.6% of AB 
strains were considered XDR and 1.4% PDR. Finally, 14-day mortality was observed in 172 (61.2%) 
patients, while 30-day mortality in 207 (73.6%) patients. 
Figure 1 shows hospital wards at time of infection onset: 83% of patients were hospitalized in ICU, 9.7% 
in medical wards, 3.6% in surgical wards, and 1.7% in emergency department. 
Table 1 shows univariate analysis comparing survivors and non-survivors at 30 days from infection 
onset. Differences between survivors and non-survivors were reported for age (53.9 ± 17.4 Vs 63.8 ± 15.9 
years, p<0.001), male sex (81.1% Vs 64.7, p=0.009), heart failure (8.1% Vs 23.7%, p=0.003), Charlson 
Comorbidity Index (3.8 ± 3.5 Vs 6.4 ± 3.9 points, p=0.004), patients transferred to ICU (9.5% Vs 16.9%, 
p=0.001), septic shock (41.9% Vs 70.5%, p<0.001), SAPS II at time of infection onset (35.7 ± 14.1 Vs 
46.6 ± 15.3 points, p<0.001), and qSOFA at time of infection onset (1.5 ± 0.9 Vs 2.1 ± 1 points, 
p=0.003). 
As reported in Table 2, Cox regression analysis of factors associated with 14-day mortality in MDR-AB 













(HR 1.44, CI95% 1.04-2, p=0.02) were associated with death, while adequate source control of infection 
(HR 0.22, CI95% 0.01-0.42, p=0.01) and combination therapy (HR 0.36, CI95% 0.01-0.89, p=0.03) were 
associated with survival. Conversely, Cox regression analysis of factors associated with 30-day mortality 
showed that septic shock (HR 1.54, CI95% 1.04-2.27, p=0.03), previous surgery (HR 1.63, CI95% 1.16-
2.29, p=0.005), and aminoglycoside-containing regimen (HR 2.57, CI95% 1.33-4.94, p=0.005) were 
associated with death, while colistin-containing regimen (HR 0.41, CI95% 0.27-0.63, p<0.001) is 
associated with 30-day survival. 
Univariate analysis comparing patients with septic shock or not secondary to MDR-AB infection is 
reported in Table 3. In patients developing septic shock were recorded more frequently previous surgery 
(33.3% Vs 15.4%, p=0.001), pneumonia (61% Vs 42.3%, p=0.003), intra-abdominal source of infection 
(6.8% Vs 0, p=0.005), mechanical ventilation (88.5% Vs 59.3%, p<0.001), CRRT (16.4% Vs 0.9%, 
p=0.003), adequate source control of infection (47.5% Vs 19.2%, p<0.001), steroid therapy (48% Vs 
29.8%, p=0.004), if compared with patients without septic shock. Primary bacteremia was observed more 
frequently in patients without septic shock (50% Vs 25.9%, p<0.001). Finally, 30-day mortality was 
82.5% in patients with septic shock (p<0.001). 
A logistic regression analysis about risk factors associated with development of septic shock is reported 
in Table 4: previous surgery (OR 33.9, CI95% 4.86-236.82, p<0.001), CRRT (OR 15.4, CI95% 3.77-
63.09, p<0.001), no source control of infection (OR 4.21, CI95% 1.06-16.7, p=0.04), and pneumonia (OR 
5.29 CI95% 1.35-20.59, p=0.016) were independently associated with higher risk of septic shock 
associated with BSI due to MDR-AB strain.  
Characteristics of antibiotic regimens in definitive therapy used in overall population are reported in 
Table 5. Monotherapy was the choice for 46 (16.3%) patients; a combination of two antibiotics was used 
in 133 (47.3%) patients; the use of a colistin-containing regimen was used for 231 (82.2%) patients, and a 













cases; in combination therapy mainly with a carbapenem (73.5% of cases), and tigecycline (34.5% of 
cases). No differences were reported in 30-day mortality about monotherapy or combination therapy with 
colistin (15 [37.5%] Vs 131 [68.5%] patients, p=0.06).  The colistin aerosol inhalation therapy was used 
in 28 (9.9%) patients; the time to initial definitive therapy was 4.4 ± 1.2 days. Comparison between 
characteristics of patients treated with monotherapy and combination therapy is reported in Table 6. 
Older age (67.7 ± 15.2 Vs 59.9 ± 16.8 years, p=0.004), and >2 comorbidities (54.3% Vs 21.2%, p=0.001) 
were reported more frequently in patients treated with monotherapy; conversely, adequate source control 
of infection (42.1% Vs 10.9%, p<0.001), transfer in ICU (33% Vs 19.5%, p=0.004), and higher SAPS II 
at time of infection (44.7 ± 15.1 Vs 39 ± 17.8 points, p=0.02) were more frequent in patients treated with 
combination therapy. Finally, statistically significant differences were reported for 14-day mortality 
(p<0.001), but not for 30-day mortality. Rates of 30-day mortality in patients treated with monotherapy 
(71.7%), combination therapy (74.04%), two-drug combination (70.6%), three-drug combination 
(78.3%), four drug combination (68.7%), colistin-containing (70.9%), and carbapenem-containing 
regimens (73.1%) are reported in Figure 2. 
Finally, Kaplan-Meier analysis of 14- and 30-day survival of patients treated with monotherapy or 





























In the present study we observed very high rates of 14-day (61.2%) and 30-day (73.6%) mortality; most 
of patients developed septic shock (62.9%) with a very high mortality (82.5%). The high mortality related 
to Acinetobacter baumannii infections was firstly reported in patients with hematologic malignancies 
[25]; afterwards, Freire et al. evaluated mortality in cancer patients with BSI caused by MDR-AB, with 7-
day and 30-day mortality rates of 71.7% and 83.7%, respectively [26]. Recent studies confirmed these 
data with mortality over 90% in patients with septic shock [12-13]. Moreover, our data show that MDR-
AB BSI remains a peculiar ICU-acquired infection, although is now more frequently observed even in 
medical and surgical wards.  
Risk factors affecting 14- and 30-day outcome have been explored in our population. As previously 
reported in literature, these data confirm the weight of comorbidities and septic shock in determining 
higher 30-day mortality [3,13,16]. Interestingly, previous surgery was associated with 30-day mortality 
while adequate source control with 14-day survival. These observations emphasize the role of early 
source control, that remains particularly complicated in abdominal surgical patient. 
Different antibiotic combinations have been studied for treatment of severe infections sustained by MDR-
AB [27-28]; in this context, the role of aerosolized colistin as adjunctive treatment for treatment of severe 













AB infections mortality was not reduced by addition of rifampicin to colistin; further in vitro studies 
explored the synergism of some drug combinations, especially colistin plus carbapenem for treatment of 
MDR-AB infections [33-34], suggesting the advantage of this combination based on high in vitro synergy 
rates. Combination of a carbapenem plus colistin seems to be the first option for treatment of MDR-AB 
infections [35], even in our population. Recently, Paul and coworkers reported data from a randomised 
controlled trial comparing colistin alone versus colistin plus meropenem for treatment of severe infections 
caused by carbapenem-resistant Gram-negative bacteria [17]. Authors concluded that combination 
therapy was not more efficient than monotherapy, and that adding meropenem to colistin did not improve 
clinical failure in severe MDR-AB infections. Of importance, Dickstein and coworkers performed a 
subgroup analysis on patients with Acinetobacter infections and reported that colistin monotherapy was 
associated with a better outcome compared to colistin-meropenem combination therapy [36]. It is 
important to underline that studies comparing efficacy of monotherapy (mainly colistin) with combination 
regimens for Acinetobacter baumannii infections included a spectrum of different severe infections, like 
ventilator associated pneumonia, but not always associated with bacteremia. On this basis, our study 
confirms that comparative studies on MDR-AB therapy should include bacteremic patients. In our 
population, combination therapy was associated with higher survival at 14 days, but no differences were 
reported at 30 days if compared to monotherapy (see Figure 3); however, all patients (except in 1 case) 
treated with monotherapy died in the first 14 days from the diagnosis of BSI (see Table 4). In our 
interpretation, sepsis and septic shock are associated with a lethal cascade of events that is unlikely to be 
interrupted even by an appropriate initial antimicrobial treatment. In addition, most of our patients were 
severely ill and would probably have been unable to survive their infections independently of the 
administration of an adequate initial antimicrobial treatment.   
Despite the relevant association between colistin use and 30-day survival, recent EUCAST 













colistin in approximately 50% of Acinetobacter baumannii strains with automated systems or Etest. 
Therefore, the very high rates of mortality observed in our population and in published studies [13,26] 
might be also attributed to a reported false susceptibility to colistin in patients for whom physicians were 
confident in the prescribing a colistin-based regimen. In strains with a real susceptibility to colistin the 
use of this drug was associated with long term survival in severe infections.  
Finally, interesting data observed in our population show the association between aminoglycoside-
containing regimen and 30-day mortality. A possible explanation should be that in a significant 
proportion of patients (54%), especially septic ones (61%), pneumonia was reported as primary source of 
infection. As reported above, severe pneumonia remains a difficult-to-treat infection and, considering the 
poor lung penetration of aminoglycosides, these drugs should be probably avoided for MDR AB 
pneumonia [39-40].  
Our study reveals some limitations that should be acknowledged. Firstly, the observational nature of the 
study brings about an intrinsic limitation in the analysis. Secondly, overall incidence of BSI caused by 
MDR-AB strains was very inhomogeneous in the involved centres. Finally, the underlying mechanisms 
of resistance in these strains were not routinely assessed and in vitro synergistic combinations were not 
performed, except for few cases. Further analysis about in vitro activity of antibiotic regimens have been 
avoided, considering that 91 (32.3%) of patients were treated for a previous MDR infections with similar 
antibiotic regimens. Moreover, antibiotic regimens with two or more drugs displaying in vitro activity 
against MDR-AB have been observed in <10% of strains. However, this real-life clinical experience from 
prestigious hospitals in Italy provides useful suggestions to clinicians about management of this difficult-
to-treat infection. 
In conclusion, BSI caused by MDR-AB strains represents a challenge for physicians, considering the high 
rates of septic shock and mortality associated with this infection. Our data showed peculiar clinical 













colistin. The lack of scientific data might explain the very high mortality rate observed in this population 
of patients [41-42]. 
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n= 74 (%) 
Non-survivors 




Age, mean ± SD (years) 53.9 ± 17.4 63.8 ± 15.9 2.2 (1.9-4.1) <0.001 
Male sex 60 (81.1) 134 (64.7) 0.42 (0.2-0.7) 0.009 
Comorbidities 
    Chronic liver disease 
    Neoplasm 
    Diabetes 
    Heart failure 
    Coronary artery disease 
    Chronic renal disease 
    COPD 
    Neurological disease 









































>2 comorbidities 27 (36.4) 48 (23.1) 0.91 (0.5-1.3) 0.59 
Charlson Comorbidity Index, mean ± SD 3.8 ± 3.5 6.4 ± 3.9 3.1 (2.4-4.8) 0.004 
Previous hospitalization (90 days) 26 (35.1) 69 (33.3) 0.92 (0.6-1.5) 0.77 
Previous ICU admission (90 days) 7 (9.5) 29 (14) 1.55 (0.7-1.9) 0.41 
Previous surgery (30 days) 11 (14.8) 64 (30.9) 2.77 (2.1-5.2) 0.004 
Previous antibiotic therapy (30 days) 38 (51.4) 115 (55.6) 1.18 (0.8-1-7) 0.58 
Previous Acinetobacter spp colonization/infection 4 (5.4) 8 (3.8) 0.85 (0.6-1.2) 1.0 
Acinetobacter colonization prior infection 11 (14.9) 20 (9.7) 0.61 (0.5-1-3) 0.27 
Source of infection 
   Primary bacteremia 
   CVC-related bacteremia 
   Pneumonia  

































   SSTI 









Fever 24 (32.4) 31 (14.9) 0.8 (0.5-1-8) 0.67 
NIV 2 (2.7) 7 (3.3) 2.25 (0.8-2.8) 0.48 
Mechanical ventilation 33 (44.5) 61 (29.4) 0.65 (0.4-1.7) 0.24 
CRRT 8 (10.8) 22 (10.6) 1.01 (0.8-1.1) 0.2 
ECMO 2 (2.7) 2 (0.9) 0.6 (0.4-1.8) 0.63 
Inadequate source control of infection 22 (29.7) 82 (39.7) 1.51 (0.8-1.9) 0.16 
Previous MDR infections during hospital stay 30 (40.5) 62 (30) 0.62 (0.4-1.3) 0.11 
PCT at time of infection onset, mean ± SD 18.2 ± 49.8 33.9 ± 68.1 1.7 (0.8-1.9) 0.26 
CRP at time of infection onset, mean ± SD 29.9 ± 51.3 51.1 ± 83.9 1.3 (0.7-2) 0.25 
Steroid therapy  28 (37.8) 88 (42.5) 1.21 (0.8-1.8) 0.49 
Transfer in ICU 7 (9.5) 35 (16.9) 7.5 (2.2-9.3) 0.001 
Septic shock 31 (41.9) 146 (70.5) 3.32 (2.5-8.9) <0.001 
Length of hospitalization, mean ± SD (days) 54.2 ± 35.6 32.5 ± 27.3 0.6 (0.2-0.8) <0.001 
Length of ICU stay, mean ± SD (days) 42.9 ± 30.4 24.1 ± 22.7 0.5 (0.3-0.7) <0.001 
Length of definitive antibiotic therapy, mean ± SD 
(days) 
15.1 ± 8.2 8.4 ± 8.3 0.63 (0.4-0.9) <0.001 
SAPS II at time of infection onset, mean ± SD 35.7 ± 14.1 46.6 ± 15.3 2.1 (1.8-4.2) <0.001 
qSOFA at time of infection onset, mean ± SD 1.5 ± 0.9 2.1 ± 1 1.2 (1.1-2.3) 0.003 
SOFA at time of infection onset, mean ± SD 6.2 ± 3 7.2 ± 3.1 1.1 (0.8-1.4) 0.11 
Legend. OR: odds ratio; SD: standard deviation; COPD: chronic obstructive pulmonary disease; SOT/HSCT: solid organ 
transplant/hematopoietic stem cell transplant; ICU: intensive care unit; CVC: central venous catheter; SSTI: skin and soft-
tissue infection; NIV: non-invasive ventilation; CRRT: continuous renal replacement therapy; ECMO: extracorporeal 
membrane oxygenation; MDR: multidrug-resistant; PCT: procalcitonin; CRP: c-reactive protein; SAPS: simplified acute 








































Table 2. Cox regression analysis about risk factors associated with 14-day and 30-day mortality 

















Septic shock 10.79 1.12-141 0.04 Septic shock 1.54 1.04-2.27 0.03 
Adequate source control of 
infection 
0.22 0.01-0.42 0.01 
Colistin-containing regimen 0.41 0.27-0.63 <0.001 
Charlson Comorbidity Index>3 
1.44 1.04-2 0.02 
Aminoglycoside-containing 
regimen 
2.57 1.33-4.94 0.005 
Combination therapy 0.36 0.01-0.89 0.03 Previous surgery (30 days) 1.63 1.16-2.29 0.005 





























Table 3.  Univariate analysis comparing patients developing or not septic shock   
Variables 
No septic shock 
n= 104 (%) 
Septic shock 
n= 177 (%) 
OR P 
Age, mean ± SD (years) 58.6 ± 18.1 62.7 ± 15.8 2.07 (0.8-2.4) 0.46 
Male sex 74 (71.2) 120 (67.8) 0.7 (0.5-1.4) 0.59 
Comorbidities 
    Chronic liver disease 
    Neoplasm 
    Diabetes 
    Heart failure 
    Coronary artery disease 
    Chronic renal disease 
    COPD 
    Neurological disease 









































>2 comorbidities 44 (42.3) 31 (17.5) 0.8 (0.5-1.4) 0.72 
Charlson Comorbidity Index, mean SD 5.1 ± 4 5.3 ± 3.9 1.26 (0.8-1.4) 0.85 
Previous hospitalization (90 days) 40 (38.5) 55 (31.1) 0.72 (0.5-1.3) 0.24 
Previous ICU admission (90 days) 12 (11.5) 24 (13.6) 1.2 (0.6-1.9) 0.71 
Previous surgery (30 days) 16 (15.4) 59 (33.3) 2.76 (1.5-4.6) 0.001 
Previous antibiotic therapy (30 days) 59 (56.7) 94 (53.1) 0.86 (0.3-1.3) 0.62 
Previous Acinetobacter spp colonization/infection 4 (3.8) 8 (4.5) 3.42 (0.9-3.9) 0.06 
Acinetobacter colonization prior infection 11 (10.6) 20 (11.3) 1.07 (0.9-1.2) 1.0 
Source of infection 
   Primary bacteremia 
   CVC-related bacteremia 





























   Catheter-related urinary tract  
   SSTI 













Fever 37 (35.5) 18 (10.1) 0.51 (0.4-1.2) 0.13 
NIV 7 (8.6) 2 (3.8) 0.41 (0.2-1.3) 0.48 
Mechanical ventilation 48 (59.3) 46 (88.5) 5.27 (3.1-7.2) <0.001 
CRRT 1 (0.9) 29 (16.4) 3.66 (2.8-5.8) 0.003 
ECMO 1 (0.9) 3 (1.6) 4.8 (0.8-4.8) 0.3 
Inadequate source control of infection 20 (19.2) 84 (47.5) 3.79 (3.1-6.4) <0.001 
Previous MDR infections during hospital stay 43 (41.3) 49 (27.7) 0.54 (0.2-0.7) 0.02 
PCT at time of infection onset, mean ± SD 19.1 ± 45.2 37 ± 75.8 1.7 (0.8-2.2) 0.198 
CRP at time of infection onset, mean ± SD 38.6 ± 55.9 51.2 ± 95.8 1.4 (0.8-1.7) 0.45 
Steroid therapy  31 (29.8) 85 (48) 2.17 (2-5.1) 0.004 
Transfer in ICU 23 (22.1) 19 (10.7) 0.33 (0.1-0.6) 0.009 
Length of hospitalization, mean ± SD (days) 47.6 ± 37.8 32.7 ± 25 0.87 (0.4-0.9) <0.001 
Length of ICU stay, mean ± SD (days) 31.3 ± 33.2 26.2 ± 21.6 0.5 (0.3-1.3) 0.13 
Length of definitive antibiotic therapy, mean ± SD 
(days) 
11 ± 7.7 9.7 ± 9.3 0.98 (0.5-1.3) 0.2 
SAPS II at time of infection onset, mean ± SD 37.4 ± 16.4 47.4 ± 14 1.9 (1.2.2.6) <0.001 
qSOFA at time of infection onset, mean ± SD 1.5 ± 0.9 2.45 ± 0.9 2.4 (1.9-3.2) <0.001 
SOFA at time of infection onset, mean ± SD 6.1 ± 2.6 8.1 ± 3.5 2.3 (1.8-3.8) 0.004 
30-day mortality 61 (58.7) 146 (82.5) 3.32 (2.4-5.3) <0.001 
Legend. OR: odds ratio; SD: standard deviation; COPD: chronic obstructive pulmonary disease; SOT/HSCT: solid organ 
transplant/hematopoietic stem cell transplant; ICU: intensive care unit; CVC: central venous catheter; SSTI: skin and soft-
tissue infection; NIV: non-invasive ventilation; CRRT: continuous renal replacement therapy; ECMO: extracorporeal 
membrane oxygenation; MDR: multidrug-resistant; PCT: procalcitonin; CRP: c-reactive protein; SAPS: simplified acute 





































Previous surgery (30 days) 33.9 4.86-236.82 <0.001 
CRRT 15.4 3.77-63.09 <0.001 
Inadequate source control of infection 4.21 1.06-16.7 0.04 
Pneumonia 5.29 1.35-20.59 0.016 




























Table 5. Antibiotic regimens as definitive therapy among overall population 
ANTIBIOTIC THERAPY* 
Overall population 
n= 281 (%) 
Use of only 1 antibiotic as definitive therapy 46 (16.3) 
Use of 2 antibiotics in combination as definitive therapy 133 (47.3) 
Use of 3 antibiotics in combination as definitive therapy 74 (26.3) 
Use of 4 antibiotics in combination as definitive therapy 16 (5.6) 
Use of 5 antibiotics in combination as definitive therapy 1 (0.4) 
Colistin-containing regimen as definitive therapy 231 (82.2) 
Tigecycline-containing regimen as definitive therapy 69 (24.5) 
Aminoglycoside-containing regimen as definitive therapy 16 (5.7) 
Rifampin-containing regimen as definitive therapy 71 (25.2) 
Ampicillin/sulbactam-containing regimen as definitive therapy 2 (0.7) 
Fosfomycin-containing regimen as definitive therapy 4 (1.4) 
Trimethoprim/sulfamethoxazole-containing regimen as definitive therapy 5 (1.7) 
Vancomycin-containing regimen as definitive therapy 14 (4.9) 
Carbapenem-containing regimen as definitive therapy 194 (69) 
Use of colistin aerosol inhalation therapy 28 (9.9) 
Time to initial definitive therapy, mean ± SD (days) 4.4 ± 1.2 
Legend. SD: standard deviation. 
*During the study period, the usual antimicrobial dosages, adopted for the most used antibiotics, were the following: for 
colistin, a loading dose of 9 million IU followed by 4.5 million IU every 12 h; for tigecycline, a loading dose of 150 to 200 mg 
followed by 100 mg every 12 h; for gentamicin, a dosage of 5 mg/kg every 24 h; for rifampin, a dosage of 10 mg/kg/day; for 
meropenem, a dosage of 2 g every 8 h or 1.5 g every 6 h; for fosfomycin 12-24 g/day divided every 6-8 h; for 
ampicillin/sulbactam 3 g every 6 h; for trimethoprim/sulfamethoxazole 15-20 mg/kg/day divided every 6 h; for vancomycin 40 




























Age, mean ± SD (years) 67.7 ± 15.2 59.9 ± 16.8 0.004 
Male sex 30 (65.2) 164 (69.8) 0.6 
Comorbidities 
    Chronic liver disease 
    Neoplasm 
    Diabetes 
    Heart failure 
    Coronary artery disease 
    Chronic renal disease 
    COPD 
    Neurological disease 































>2 comorbidities 25 (54.3) 50 (21.2) 0.001 
Charlson Comorbidity Index, mean SD 5.5 ± 3.1 5 ± 4.3 0.64 
Previous hospitalization (90 days) 22 (47.8) 73 (31.1) 0.04 
Previous ICU admission (90 days) 5 (10.9) 31 (13.2) 0.81 
Previous surgery (30 days) 10 (21.7) 65 (27.6) 0.7 
Previous antibiotic therapy (30 days) 28 (60.9) 125 (53.2) 0.41 
Previous Acinetobacter spp colonization/infection 1 (3.3) 10 (9.6) 0.29 
Acinetobacter colonization prior infection 5 (10.9) 26 (11.1) 1.0 
Source of infection 
   Primary bacteremia 
   CVC-related bacteremia 
   Pneumonia  
   Catheter-related urinary tract  
   SSTI 



































NIV 2 (4.3) 7 (2.9) 1.0 
Mechanical ventilation 15 (32.6) 79 (33.6) 0.07 
CRRT 7 (15.2) 23 (9.7) 1.0 
ECMO 1 (2.1) 3 (1.2) 1.0 
Source control of infection 5 (10.9) 99 (42.1) <0.001 
Previous MDR infections during hospital stay 21 (45.7) 71 (30.2) 0.05 
PCT at time of infection onset, mean ± SD 34.2 ± 96.7 25.4 ± 51.6 0.63 
CRP at time of infection onset, mean ± SD 69.4 ± 114.2 36.1 ± 57.1 0.09 
Steroid therapy  18 (39.1) 98 (41.7) 0.87 
Transfer in ICU 9 (19.5) 33 (14) 0.004 
Septic shock 26 (56.5) 151 (64.3) 0.32 
Length of hospitalization, mean ± SD (days) 32.6 ± 30.3 39.3 ± 31.2 0.18 
Length of ICU stay, mean ± SD (days) 13.8 ± 11 30.1 ± 27.2 <0.001 
Length of definitive antibiotic therapy, mean ± SD 
(days) 
8.3 ±.2 10.5 ± 9.3 0.14 
SAPS II at time of infection onset, mean ± SD 39 ± 17.8 44.7 ± 15.1 0.02 
qSOFA at time of infection onset, mean ± SD 1.9 ± 1 1.8 ± 1 0.75 
SOFA at time of infection onset, mean ± SD 6.5 ± 2.6 7 ± 3.2 0.51 
14-day mortality 32 (69.5) 140 (59.5) <0.001 
30-day mortality 33 (71.7) 174 (74) 0.71 
Legend. SD: standard deviation; COPD: chronic obstructive pulmonary disease; SOT/HSCT: solid organ 
transplant/hematopoietic stem cell transplant; ICU: intensive care unit; CVC: central venous catheter; SSTI: skin and soft-
tissue infection; NIV: non-invasive ventilation; CRRT: continuous renal replacement therapy; ECMO: extracorporeal 
membrane oxygenation; MDR: multidrug-resistant; PCT: procalcitonin; CRP: c-reactive protein; SAPS: simplified acute 















































































Figure 3. Kaplan-Meier curves about 14-day (A) and 30-day (B) survival of patients treated with 
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